Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy
A clinical trial is underway to evaluate iberdomide maintenance therapy against lenalidomide maintenance following ASCT in NDMM patients.
Asset / Drug
Drug and asset intelligence for Iberdomide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.